Lates News

UBS released a research report stating that CanSino Biologics' performance in the second quarter slightly exceeded expectations, with revenue growth accelerating to 38% compared to 20% in the first quarter. Net losses narrowed to 2 million yuan, with a net loss of 13 million yuan in the first half of the year, a 94% decrease compared to the same period last year, which was lower than the bank's forecast of a loss of 31 million yuan. Management reiterated the full-year revenue guidance of 1 billion yuan. UBS reiterated its positive outlook on CanSino Biologics as the preferred stock in the vaccine sector, expecting its profit growth to accelerate and believing that its early pipeline products and licensing potential have not been fully reflected. The bank raised its target price from 47 Hong Kong dollars to 66.6 Hong Kong dollars, reaffirming a "buy" rating, and raised its earnings forecasts for 2025 to 2027 from 0.01, 1.16, and 2.39 yuan per share to 0.24, 1.16, and 2.55 yuan per share.